Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | MET | P08581 | 5/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14579509 | 0.73 | KDR (0.42) | MAPTKDRTDP1 | |
| SCHEMBL14252959 | 0.71 | MAP4K4 (0.62) | TSHRTDP1 | |
| SCHEMBL18033869 | 0.69 | EGFR (0.35) | KDR | |
| SCHEMBL4278057 | 0.68 | KDR (0.60) | KDR | |
| SCHEMBL14017264 | 0.67 | ERBB2 (0.38) | KDRTSHR | |
| SCHEMBL12872519 | 0.66 | ALDH1A1 (0.44) | MAPTTSHRTDP1 | |
| SCHEMBL4047329 | 0.64 | MET (0.59) | KDRMET | |
| SCHEMBL1962838 | 0.63 | AXL (0.38) | MET | |
| SCHEMBL12872522 | 0.62 | ALDH1A1 (0.47) | MAPTKDRTSHRTDP1 | |
| SCHEMBL15221821 | 0.62 | FGFR1 (0.39) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7432373-B2 | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2008-10-07 | — | — | US | disclosed |
| US-7348325-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070123534-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123534-A1 | Pyrrolotriazine kinase inhibitors | MAP3K15, MAP3K5, STK25 | MAPT 1469/4885KDR 1433/4885MET 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.